Firm's vision is to harness power of microorganisms as a sustainable platform to produce proteins now derived from animals ...
Travere Therapeutics Stock (TVTX) is plummeting on news of a potential FDA delay for its kidney disease treatment ...
The U.S. Food and Drug Administration approved Fortress Biotech and Indian drugmaker Zydus Lifesciences' drug for children ...
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR ...
At a STAT event, veteran drug regulator Richard Pazdur, who left the FDA last month after 26 years, said that politics and ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for ...
Stoke Therapeutics and the FDA were unable to reach agreement on an expedited submission for the company’s severe epilepsy ...
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...
Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy ...
Since January, leading pharma and biotech companies have pledged $520 billion to expand their manufacturing capacity in the ...
Investor's Business Daily on MSN
IBD stock of the day Medpace tests early buy point as biotech funding shines
Medpace Holdings is Tuesday's IBD Stock Of The Day. Shares are testing an early entry as the biotech funding environment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback